- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.04. | Novo partners with telehealth companies in move to expand Wegovy market | ||
| 29.04. | FDA misses approval deadline for biotech's rare disease drug | ||
| 29.04. | Abeona cell therapy approved by FDA for rare skin condition | ||
| 28.04. | Novavax says vaccine application still 'approvable,' despite FDA delay | ||
| 28.04. | Merck KGaA to buy biotech SpringWorks for $3.9B | ||
| 28.04. | New Akeso, Summit data stir debate on PD-1/VEGF drugs | ||
| 28.04. | Top Republican calls for 340B reform in long-awaited investigation | ||
| 28.04. | How integrated real-world data helps identify and improve outcomes for rare disease patients | ||
| 25.04. | Biohaven stock slides on withdrawal of European marketing application | ||
| 25.04. | Gilead leans on HIV drugs as oncology sales slow | ||
| 25.04. | Halozyme sues Merck; FDA blames cuts for Vanda delay | ||
| 25.04. | Caribou, in reversal, scraps autoimmune cell therapy and cuts staff | ||
| 24.04. | Bristol Myers says schizophrenia drug launch 'off to a solid start' | ||
| 24.04. | Merck takes $200M tariff hit, trimming its gross profits | ||
| 24.04. | Sanofi stays course amid tariff turmoil | ||
| 24.04. | Versant startup Granite debuts with $100M and two immune drugs | ||
| 24.04. | Etiome, a new Flagship startup, looks to catch disease before it strikes | ||
| 23.04. | [Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care | ||
| 23.04. | German antibody maker Veraxa Biotech valued at $1.6B in blank-check merger | ||
| 23.04. | Bristol Myers' prized schizophrenia drug stumbles in testing | ||
| 23.04. | Roche looks to a Flagship startup in search of new immune drugs | ||
| 22.04. | Roche, answering tariff threat, pledges $50B to US drug production | ||
| 22.04. | Former Neumora CEO to lead Galapagos spinout | ||
| 22.04. | The Trump administration is remaking HHS. Track the changes here. | ||
| 22.04. | Arkansas passes law banning PBMs from owning pharmacies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .